阿伐可泮在西班牙常规实践中治疗ANCA相关性血管炎的真实世界使用与有效性:首批经验
该研究纳入2022年6月至2023年9月期间在西班牙早期准入项目中启动阿伐可泮治疗的29例ANCA相关性血管炎患者,并设历史对照。结果显示阿伐可泮联合标准免疫抑制治疗安全性良好,6个月和12个月泼尼松累积剂量显著低于历史对照,1年肾小球滤过率演变和复发率两组相似。
要点
- 阿伐可泮组29例,中位年龄56岁,ANCA MPO阳性21/29(72.4%),肾脏受累23/29(79.31%)。
- 阿伐可泮组6个月和12个月泼尼松累积剂量显著低于历史对照(P值分别为0.02和<0.01)。
- 1年随访时肾小球滤过率演变和复发发生率两组相似。
核心结论
- 阿伐可泮联合标准免疫抑制治疗安全性良好,有助于控制ANCA相关性血管炎活动、提高肾小球滤过率并减少激素使用。
研究设计与样本
- 纳入2022年6月至2023年9月期间启动阿伐可泮治疗的ANCA相关性血管炎患者,并设同期诊断、未使用阿伐可泮治疗的历史队列作对照。
主要发现
- 阿伐可泮组共29例,男性12例(41.4%),中位年龄56岁,ANCA MPO阳性21/29(72.4%),肾脏受累23/29(79.31%),平均eGFR为23.2 ml/min。
- 平均随访456.8(±181.7)天,缓解率86.2%。
- 诊断后12个月eGFR从23.2(11.2)ml/min升至38.38(18.55)ml/min。
- 2例发生与阿伐可泮相关的不良事件(严重中性粒细胞减少和胃肠道受累),报告13例感染和1例死亡。
- 与历史对照相比,阿伐可泮组6个月和12个月泼尼松累积剂量显著更低(P值分别为0.02和<0.01);1年随访时GFR演变和复发发生率两组相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: ANCA-associated vasculitis (AAV) is a group of chronic diseases with relapses that associate organic damage because of the disease and its treatment. Avacopan is a new treatment indicated for AAV. We present the first experiences with avacopan in Spain as part of an Early Access program. METHODS: Patients with AAV who started avacopan between June 2022 and September 2023 were included. For comparison, a historical cohort of patients diagnosed with AAV around the same time and treated without avacopan was also included. RESULTS: Twenty-nine patients treated with avacopan were analysed. Twelve patients (41.4%) were male, and median age was 56 years. Most patients were ANCA MPO positive (21/29, 72.4%). The most frequently affected organ was the kidney (23/29, 79.31%), with a mean estimated glomerular filtration rate (eGFR) of 23.2 ml/min. Mean follow-up was 456.8 (±181.7) days with a remission rate of 86.2%. eGFR increased from 23.2 (11.2) to 38.38 (18.55) ml/min after 12 months of diagnosis. Two patients had adverse events related to avacopan (severe neutropenia and a gastrointestinal affectation), 13 infections were reported and one death. Patients treated with avacopan received a significantly lower cumulative dose of prednisone at 6 and 12 months (P-values of 0.02 and <0.01, respectively) compared with historical controls. The evolution of GFR at 1 year of follow-up and the incidence of relapse were similar in both groups. CONCLUSION: The combination of avacopan with standard immunosuppressive therapy presents a good safety profile and provides added value by contributing to the control of AAV activity, increase GFR and removal of steroids.
引用
- Draibe J, Espigol-Frigolé G, Cid MC, et al. The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain. Rheumatology (Oxford). 2025. PMID: 39352795. doi:10.1093/rheumatology/keae534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。